Press
-
Biotech VCs Move Upstream in China’s Scientific Pipelines as Competition Grows Fiercer
The following excerpt was taken from STAT News—continue reading here. U.S. venture capital firms are no longer waiting for Chinese biotech assets to surface before investing in them — they’re moving upstream, embedding themselves inside labs and courting scientists before they publish their research. In some cases, they’re vying against Chinese VCs urging scientists not to